

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 February 2025 (13.02.2025)



(10) International Publication Number
WO 2025/034951 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/166 (2006.01)
A61K 31/165 (2006.01)

(21) International Application Number:

PCT/US2024/041436

(22) International Filing Date:

08 August 2024 (08.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/531,637 09 August 2023 (09.08.2023) US
63/607,506 07 December 2023 (07.12.2023) US
63/667,539 03 July 2024 (03.07.2024) US

(71) Applicant: **ENANTA PHARMACEUTICALS, INC.**
[US/US]; 500 Arsenal Street, Watertown, MA 02472 (US).

(72) Inventors: **ZHANG, Jiajun**; 42 Maple Ave, #2, Cambridge, MA 02139 (US). **SIU, Yuk, Ming**; 270 Pleasant Street, Apt. 437, Watertown, MA 02472 (US). **XU, Peilin**; 204 Arsenal St., Apt 251, Watertown, MA 02472 (US). **RHODES, Matthew C.**; 192 Allston St., Apt. 2, Boston, MA 02134 (US). **CAO, Hui**; 49 Thayer Rd, Belmont, MA 02478 (US). **OR, Yat Sun**; 29 Michaelchris Drive, Waltham, MA 02452 (US). **GAO, Xuri**; 15 Walker Street, Newtonville, MA 02460 (US). **LI, Wei**; 64 Prospect Hill Rd, Lexington, MA 02421 (US). **XING, Xuechao**; 20 Cedar Street, Wilmington, MA 01887 (US). **MITCHELL, Scott**; 30 Eaton Avenue, Woburn, MA 01801 (US).

(74) Agent: **HARLAN, Edgar W.** et al.; Elmore Patent Law Group, P.C., 484 Groton Road, Westford, MA 01886 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,


RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS



(57) Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFR α , PDGFR β) kinases.



WO 2025/034951 A1